Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tenofovir disoproxil
Drug ID BADD_D02155
Description Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name _Viread_, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is prescribed in combination with other drugs for the management of HIV infection as well as for Hepatitis B therapy. Tenofovir disoproxil was initially approved in 2001 [FDA label].
Indications and Usage Tenofovir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older. It is also indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
Marketing Status Prescription
ATC Code J05AF07
DrugBank ID DB00300
KEGG ID D01982
MeSH ID D000068698
PubChem ID 5481350
TTD Drug ID D0D9HW
NDC Product Code 68554-0046
Synonyms Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine | 9-PMPA (tenofovir) | 9-(2-Phosphonomethoxypropyl)adenine | 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer | 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer | Tenofovir Disoproxil Fumarate | Disoproxil Fumarate, Tenofovir | Fumarate, Tenofovir Disoproxil | Tenofovir Disoproxil | Disoproxil, Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 | (R)-9-(2-phosphonylmethoxypropyl)adenine | Viread
Chemical Information
Molecular Formula C19H30N5O10P
CAS Registry Number 201341-05-1
SMILES CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver injury09.01.07.022; 12.01.02.0030.048872%Not Available
Low birth weight baby18.04.02.0030.008886%Not Available
Focal segmental glomerulosclerosis20.05.01.0030.017772%Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.0020.002318%Not Available
Fasting26.01.02.001--Not Available
Acute kidney injury20.01.03.0160.217703%
Hepatitis B virus test positive13.08.03.0100.013329%Not Available
Foetal growth restriction18.03.01.0020.003477%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.035543%Not Available
Hepatic cancer16.07.02.004; 09.04.02.0080.018544%Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.025499%Not Available
Liver function test increased13.03.01.044--Not Available
Abortion threatened18.01.04.0030.008886%Not Available
Congenital umbilical hernia03.04.07.006; 07.16.03.0030.013329%Not Available
Cryoglobulinaemia24.05.02.019; 10.04.04.0130.008886%Not Available
Glomerular filtration rate abnormal13.13.01.0220.013329%Not Available
HIV test positive13.08.03.0060.079973%Not Available
IgA nephropathy20.05.01.016; 10.02.01.0630.013329%Not Available
Maternal drugs affecting foetus18.03.03.009; 12.03.03.0060.008886%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.008886%Not Available
Small for dates baby18.04.02.0020.008886%Not Available
Spinal column stenosis17.10.01.011; 15.10.04.0030.008886%Not Available
Cholestasis of pregnancy18.02.04.003; 09.01.01.0130.013329%Not Available
Live birth18.08.02.0070.008886%Not Available
Lumbar vertebral fracture15.08.05.007; 12.04.04.0070.017772%Not Available
Mitochondrial cytopathy14.11.02.0080.006954%Not Available
Meconium in amniotic fluid18.05.01.0070.008886%Not Available
Congenital pulmonary valve atresia03.07.05.009; 02.07.04.0030.013329%Not Available
Hepatitis B DNA assay positive13.08.03.0180.044429%Not Available
Glomerulosclerosis20.05.03.0080.005795%Not Available
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages